Advanced search
Publication Cover
Journal of Medical Economics Volume 23, 2020 - Issue 1
Submit an article Journal homepage
2,841
Views
2
CrossRef citations to date
0
Altmetric
Oncology

Healthcare resource utilization and costs associated with patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive NSCLC in the United States

Carl SamuelsenBoehringer Ingelheim International GmbH, Ingelheim, Germany; Correspondence[email protected]
,
Jonathan LimBoehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, USA;
,
Amanda GolembeskyBoehringer Ingelheim International GmbH, Ingelheim, Germany;
,
Sulena ShresthaSTATinMED Research, Plano, TX, USA
,
Li WangSTATinMED Research, Plano, TX, USA
&
Ingolf GriebschBoehringer Ingelheim International GmbH, Ingelheim, Germany;
Pages 48-53 | Received 17 May 2019, Accepted 16 Jul 2019, Published online: 09 Aug 2019
Supplemental material

Supplemental data for this article is available online at https://doi.org/10.1080/13696998.2019.1645681.

Download MS Word (37.4 KB)

Related Research Data

Healthcare resource utilization and costs associated with patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive NSCLC in the United States
Source: Taylor & Francis
Healthcare resource utilization and costs associated with patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive NSCLC in the United States
Source: Taylor & Francis

Linking provided by 

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.